The American Association for Pediatric Ophthalmology and Strabismus issued a statement on Tuesday endorsing a “strong case” for approving an atropine formulation for myopia, in response to the FDA’s recent nonapproval of SYD-101.
The AAPOS Myopia Task Force stated that the lack of approval for SYD-101 (0.01% atropine, Sydnexis) “has important implications for pediatric eye care, myopia control research and ongoing unmet clinical needs.”
“Dilute atropine has been approved for myopia management in several other countries for many years and has consistently